PHARMAUST Receives first $200K installment for Phase 1.MND TRIAL

PHARMAUST

PharmAust receives the first installment of $200k for phase 1 of MND trials and assigns a trial coordinator.

  • Clinical-stage biotechnology firm PharmAust (PAA) receives more than $201,000 as of the first installment payment through FightMND for its motor neuron disease Phase 1 study.
  • company has been awarded more than 881,000 dollars to study the effects of monepantel on MND.
  • Also called Lou Gehrig’s Syndrome (also known as Amyotrophic Lateral Sclerosis (ALS)
  • The company has recently completed the manufacturing of MPL that is currently Good Manufacturing Practice (cGMP) grade MPL and has achieved the first milestone of the first installment payment.
  • Furthermore, the company selected Alithia Life Sciences to manage the Phase 1 trial, and it is completely covered by FightMND’s Drug Development grant awarded by FightMND.
  • PAA Shares are trading up 2.25 percent, and are the shares are trading for 9.2 cents

Also Read: Landline: RAISES $28M FOR FUNDER

Also Read: BOXHUB SELLS $2.7M in SEED SECURITY

Also Read: AVZ MINERALS: RECEIVES FAVOURABLE TECHNICAL OPINION FOR MANONO LITHIUM

Chris Evan was born in Dubai and raised in Montreal. He studied Computer Science and was so pleased with computer languages. He began writing after obsessing over technology.

Leave a Reply

Your email address will not be published.